Table 4 Comparisons between rheumatoid arthritis patients with and without subclinical atherosclerosis
Characteristic | RA patients with subclinical atherosclerosis (n = 32) | RA patients without subclinical atherosclerosis (n = 28) | p-value |
|---|---|---|---|
Age years, median (IQR) | 56.70 (51.55–65.92) | 50.00 (45.25–55.08) | 0.002 |
Female, n (%) | 29 (90.6) | 27 (96.4) | 0.616 |
T2DM, n (%) | 7 (21.9) | 3 (10.7) | 0.312 |
Hypertension, n (%) | 14 (43.8) | 6 (21.4) | 0.067 |
Dyslipidemia, n (%) | 17 (53.1) | 4 (14.3) | 0.002 |
Obesity, n (%) | 14 (43.8) | 11 (39.3) | 0.726 |
BMI, mean ± SD | 30.03 ± 4.80 | 29.47 ± 4.65 | 0.668 |
Active smoking, n (%) | 2 (6.3) | 2 (7.1) | 1.000 |
Disease duration, mean ± SD | 2.87 ± 1.41 | 2.41 ± 1.34 | 0.210 |
Duration of symptoms before diagnosis, median (IQR) | 0.49 (0.11–1.83) | 0.77 (0.12–1.58) | 0.888 |
DAS28-CRP, median (IQR) | 3.60 (2.58–4.14) | 2.63 (1.80–4.31) | 0.116 |
DAS28-CRP, n (%) | |||
Moderate-high disease activity | 22 (68.8) | 10 (35.7) | 0.010 |
CRP, median (IQR) | 0.98 (0.51–1.38) | 0.64 (0.25–1.45) | 0.133 |
ESR, median (IQR) | 20.00 (13.25–44.25) | 19.00 (12.00–29.00) | 0.257 |
Seropositivity, n (%) | |||
RF | 21 (65.6) | 21 (75.0) | 0.429 |
Anti-CCP antibodies | 13 (40.6) | 14 (50.0) | 0.466 |
MTX, n (%) | 22 (68.8) | 22 (78.6) | 0.391 |
bDMARD, n (%) | 4 (12.7) | 0 (0.0) | 0.116 |
Glucocorticoids, n (%) | 17 (53.1) | 17 (60.7) | 0.554 |